Montelukast Pharmathen S.A. (Montelukast)

Montelukast works by selectively blocking the cysteinyl leukotriene receptor CysLT1. This inhibition prevents leukotrienes—potent inflammatory mediators—from causing bronchoconstriction, mucus production, and vascular leakage, thereby reducing airway narrowing and allergic inflammation.

The appropriate dose of Montelukast is determined by the prescribing healthcare professional based on the patient’s age, condition, and response to therapy. Dosage recommendations are provided in the product labeling and should be followed exactly as instructed by the prescriber.

Safety data for Montelukast in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against any possible risks before prescribing it to pregnant or nursing women. Women should discuss their specific situation with a qualified medical professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑sensitive asthma or those who prefer a once‑daily oral regimen, though it may be less potent than inhaled steroids for severe disease.

Montelukast tablets should be stored at temperatures below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Maintaining these conditions helps preserve the product’s stability and potency throughout its shelf life.

Montelukast is taken orally, usually once daily in the evening, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include allergic reactions such as rash, angioedema, or anaphylaxis, as well as neuropsychiatric events like depression, suicidal thoughts, and behavioral changes. Liver enzyme elevations and severe skin reactions (e.g., Stevens‑Johnson syndrome) have also been reported and require immediate medical attention.

Montelukast should not be used by individuals with a known hypersensitivity to the drug or any of its excipients. It is also contraindicated in patients who have experienced severe allergic reactions to leukotriene‑modifying agents. Clinicians should evaluate each patient’s medical history before initiating therapy.